Harbin Pharmaceutical (SHA:600664) said two of its drugs were proposed to be selected for the twelfth round of China's National Centralized Drug Procurement, according to a Shanghai bourse filing on Tuesday.
The drugs, which were both produced by the company's subsidiaries, are ceftazidime avibactam sodium for injection, which is used to treat complicated intra-abdominal infections, and vonoprazan fumarate tablets, which is for the treatment of reflux esophagitis.
The pharmaceutical company's shares jumped 8% at the close.